MUSTANG BIO, INC.
MBIONasdaq
$0.63
↓ -2.5%Jul 17 close · end-of-day
Price
1Y↓ -71.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$4.2M
Enterprise Value
-$12.0M
P/E
—
P/S
—
P/B
0.5
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$2.7M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-31.7%
ROIC
—
Debt / Equity
—
Net Cash
$16.3M
Return 1Y
-72.9%
Company profile
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition.
- CEO
- Manuel Litchman
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 100
- Headquarters
- Massachusetts
- Website
- mustangbio.com
Management & directors
- Litchman Manuel MdPresident, CEO and Interim CFO
Roles derived from SEC Form 4 filings.
Earnings
MBIO Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.14↑ +180.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$56.8M | -$66.7M | -$76.2M | -$49.3M | -$16.2M | -$2.4M |
| Net income | -$60.0M | -$66.4M | -$77.5M | -$51.6M | -$15.8M | -$1.9M |
| Diluted EPS | — | -$0.76 | -$10.09 | -$299.95 | -$38.57 | -$0.39 |
| Operating cash flow | -$37.3M | -$53.7M | -$65.1M | -$49.5M | -$11.4M | -$5.3M |
| Free cash flow | -$39.2M | -$57.7M | -$67.8M | -$49.5M | -$11.4M | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$8.5M | -$1.5M | -$1.0M | -$253,000.00 | -$885,000.00 | -$624,000.00 | -$670,000.00 | -$1.1M |
| Net income | -$8.2M | -$1.4M | -$952,000.00 | -$153,000.00 | -$762,000.00 | -$468,000.00 | -$538,000.00 | -$955,000.00 |
| Diluted EPS | -$18.36 | -$1.96 | $6.56 | -$0.05 | -$0.19 | -$0.07 | -$0.08 | -$0.14 |
| Operating cash flow | -$2.3M | -$1.8M | -$2.0M | -$1.4M | -$1.3M | -$818,000.00 | -$1.7M | -$1.0M |
| Free cash flow | — | -$1.8M | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 2, 2025
Mar 5, 2025
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-04-24 | Litchman Manuel MD· President, CEO and Interim CFO | Tax withholding | 19 | $0.75 | $14.25 | filing |
| 2026-01-02 | Fortress Biotech, Inc. | Award | 278,385 | $0.00 | $0.00 | filing |
| 2025-12-30 | Herskowitz Neil | Sale | 247 | $0.96 | $237.61 | filing |
| 2025-12-30 | Jin David | Buy | 247 | $0.96 | $237.61 | filing |
| 2025-12-30 | Chill Adam J. | Sale | 4 | $0.95 | $3.82 | filing |
| 2025-09-29 | Fortress Biotech, Inc. | Award | 59,334 | $0.00 | $0.00 | filing |
Latest 6 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.